You are here

Article Text

Article menu

Download PDFPDF

Infographic
Guidelines for the use of buprenorphine for opioid use disorder in the perioperative setting
Free
  1. Lynn Kohan1,
  2. Sudheer Potru2,
  3. Antje M Barreveld3,
  4. Michael Sprintz4,
  5. Olabisi Lane5,
  6. Anuj Aryal6,
  7. Trent Emerick7,
  8. Anna Dopp8,
  9. Sophia Chhay8 and
  10. Eugene Viscusi9
  1. 1 Divsion of Pain Medicine/Department of Anesthesia, University of Virginia, Charlottesville, Virginia, USA
  2. 2 Department of Anesthesiology/Division of Pain Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
  3. 3 Department of Anesthesiology, Tufts University School of Medicine, Boston, Massachusetts, USA
  4. 4 Division of Geriatrics and Palliative Medicine, The University of Texas Health Science Center at Houston, Houston, Texas, USA
  5. 5 Department of Anesthesiology, Emory University School of Medicine, Atlanta, Georgia, USA
  6. 6 Department of Anesthesiology, VA Tennessee Valley Healthcare System Nashville Campus, Nashville, Tennessee, USA
  7. 7 Department of Anesthesiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
  8. 8 American Society Health System Pharmacists, Bethesda, Maryland, USA
  9. 9 Department of Anesthesiology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
  1. Correspondence to Dr Sudheer Potru, Atlanta VA Medical Center, Emory University School of Medicine, Atlanta, Georgia, USA; sudheer.potru{at}emory.edu

https://doi.org/10.1136/rapm-2021-103092

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Abstract

    The boards of directors of the American Society of Regional Anesthesia and Pain Medicine, American Society of Anesthesiologists, American Academy of Pain Medicine, American Society of Addiction Medicine and American Society of Health System Pharmacists approved the creation of a Multisociety Working Group on Opioid Use Disorder (OUD), representing the fields of pain medicine, addiction and pharmacy health sciences. An extensive literature search was performed, and a modified Delphi process was used to assess the literature and expert opinion for each topic, with 100% consensus being achieved on the statements and each recommendation. The consensus statements were then graded by the committee members using the US Preventive Services Task Force grading of evidence guidelines. Two core topics were identified for the development of recommendations, with both topics achieving 100% consensus: (1) providing recommendations to aid physicians in the management of patients receiving buprenorphine for medication treatment of OUD in the perioperative setting and (2) providing recommendations to aid physicians in the initiation of buprenorphine in patients with suspected OUD in the perioperative setting. To decrease the risk of OUD recurrence, buprenorphine should not be routinely discontinued in the perioperative setting. Buprenorphine can be initiated in untreated patients with OUD and acute pain in the perioperative setting to decrease the risk of opioid recurrence and death from overdose.

    Figure

    Ethics statements

    Patient consent for publication

    References

      1. Substance Abuse and Mental Health Services Administration
      . Key substance use and mental health indicators in the United States: results from the 2017 national survey on drug use and health. Available: https://www.samhsa.gov/data/report/2017-nsduh-annual-national-report [Accessed 21 Mar 2021].
      2. Sordo L ,
      3. Barrio G ,
      4. Bravo MJ , et al
      . Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ 2017;357:j1550. doi:10.1136/bmj.j1550 pmid:http://www.ncbi.nlm.nih.gov/pubmed/28446428
      OpenUrlAbstract/FREE Full Text
      2. Saitz R ,
      3. Daaleman TP
      . Now is the time to address substance use disorders in primary care. Ann Fam Med 2017;15:306–8.doi:10.1370/afm.2111 pmid:http://www.ncbi.nlm.nih.gov/pubmed/28694263
      OpenUrlFREE Full Text
      2. White SR ,
      3. Bird SM ,
      4. Merrall ELC , et al
      . Drugs-related death soon after hospital-discharge among drug treatment clients in Scotland: record linkage, validation, and investigation of risk-factors. PLoS One 2015;10:e0141073. doi:10.1371/journal.pone.0141073 pmid:http://www.ncbi.nlm.nih.gov/pubmed/26539701
      OpenUrlPubMed
      1. Federal Registrar
      . Federal guidelines on the for the administration of buprenorphine for treating OUD. Available: https://www.federalregister.gov/documents/2021/04/28/2021-08961/practice-guidelines-for-th e-administration-of-buprenorphine-for-treating-opioid-use-disorder [Accessed 28 Apr 2021].

    Footnotes

    • Twitter @kohanlynn, @SPotruDO

    • Contributors All authors participated in development of the original manuscript on which this infographic was created. LK authored the infographic.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles